Generation of genetically engineered mouse lung organoid models for squamous cell lung cancers allows for the study of combinatorial immunotherapy.

CONCLUSIONS: We developed a mouse model system to investigate a novel combinatory approach that illuminates a clinical path hypothesis for combining ICB with DNA damage-inducing therapies in the treatment of LSCC.
PMID: 32209571 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - March 23, 2020 Category: Cancer & Oncology Authors: Hai J, Zhang H, Zhou J, Wu Z, Chen T, Papadopoulos E, Dowling CM, Pyon V, Pan Y, Liu JB, Bronson RT, Silver H, Lizotte PH, Deng J, Campbell JD, Sholl LM, Ng C, Tsao MS, Thakurdin C, Bass AJ, Wong KK Tags: Clin Cancer Res Source Type: research